Introduction {#Sec1}
============

Diabetes is one of the most frequent diseases in developed countries. Every year, the incidence of this disease significantly increases. The prediction for 2030 is more than 500 million persons with diabetes, especially type 2, worldwide \[[@CR1]\]. This phenomenon results primarily from the lifestyle changes: decrease of physical effort and, above all, excess of calories from badly balanced diet, especially from fast food \[[@CR2]--[@CR6]\]. In type 1 diabetes, auto-aggression destroys β-cells and leads to insulin production atrophy. The mechanism of this type of disease is observed in a lot of laboratories \[[@CR7], [@CR8]\]. Insulin production in the pancreas is a multistage process sensitive to glucose level. Also, proper level of micro-elements, especially zinc \[[@CR9], [@CR10]\] plays an important role in secretion of this hormone. Type 1 diabetes in an animal model can be provoked by a streptozotocin (STZ) injection which destroys β-cells within 2--3 days \[[@CR11]--[@CR13]\]. During this time, the glucose level can increase to more than 30 mmol/l, with all symptoms of not treated type 1 diabetes. Since the 1980s, vanadium compounds have been tested as potential therapeutic agents in type 1 \[[@CR14]--[@CR16]\] and type 2 \[[@CR17]--[@CR20]\] diabetes. Some organic and inorganic vanadium compounds have presented interesting influence on biochemical markers like decrease of glucose level and improvement of other biochemical parameters. Negative effects of vanadium treatment on intestinal tract, such as diarrhea, vomiting etc., have been frequently reported \[[@CR21], [@CR22]\]. This was associated with high doses of administered vanadium compounds. Nowadays, scientific attempts concentrate on the decrease of negative effects and increase of therapeutic activity in both diabetes models. In particular, vanadium complexes with organic ligands present interesting proprieties \[[@CR23]--[@CR27]\] and usually higher bioavailability \[[@CR28]\]. Some of them have already been tested on patients in clinical trials \[[@CR26], [@CR27]\]. Trace elements supplementation in case of vanadium can influence not only biochemical parameters but also other element level in organs \[[@CR29], [@CR30]\]. This work focuses on a recondite effect of vanadium treatment on other levels of elements in the kidney of diabetic STZ rats.

Material and Methods {#Sec2}
====================

Animals and Vanadium Administration {#Sec3}
-----------------------------------

Male Wistar rats weighing between 220 and 250 g were divided into seven groups of six animals in each group. During all time, animals had free access to water and feed. After 3 days from the beginning of the experiment, 55 mg of streptozotocine in citric buffer (0.1 mol/l) solution per 1 kg of body mass was injected into the caudal in all groups of animals. Three days subsequent to the injections, the level of glucose was measured and the glucose level measured in animal blood was higher than 17 mmol/l. After the measurement, the rats were separated into the following tested groups: diabetic control rats (D), diabetic rats with insulin (Di), five groups of diabetic rats with insulin and tested complexes (Di1--5). The tested complexes of vanadium were administered daily in dose of 50 μmol/kg and 1 U/kg of insulin was injected subcutaneously. Five weeks after beginning of first insulin injection and vanadium complexes administration, animal were anesthetized (thiopental, 50 mg/kg) and then the kidneys were collected. For kidney collection, stainless steel chirurgical scissors and tweezers in all groups of animals were used. Kidneys were directly inserted to plastic tubes and kept frozen in −20 °C until the time of analysis. Experiment got the agreement from Local Ethic Commission in Krakow ZI/UJ/185/2003.

Used complexesNa\[VO(O~2~)~2~(2,2′-bpy)\] · 8 H~2~O (molar mass = 453.94 g/mol)Na\[VO(O~2~)~2~(1,10′-phen)\] · 5 H~2~O (molar mass = 423.94 g/mol)Na\[VO(O~2~)~2~(4,4′-Me-2,2′-bpy)\] · 8 H~2~O (molar mass = 481.94 g/mol)\[VO(SO~4~)(1,10′-phen)\] · 2 H~2~O (molar mass = 363 g/mol)\[VO(SO~4~)(2,2′-bpy)\] · H~2~O (molar mass = 321 g/mol)where synthesized by the method described in the literature \[[@CR31]--[@CR33]\].

Used abbreviation: bpy, bypiridyne; phen, phenanthroline, and Me, methyl. Their purity was confirmed by elemental analysis and infrared spectroscopy.

Kidney Tissue Preparation {#Sec4}
-------------------------

Frozen kidney tissue was transferred directly to lyophilizing cabinet and lyophilized using ABCONO FREEZONE 4,5 in temperature from −40 to −53 °C, and under pressure of 14--1 Pa. Then, the lyophilized kidney tissue was homogenated in agate mortar and pressed into pellets, about 1 mm thick and 10 mm in diameter, by pressure of 15 MPa in home-made apparatus. Such pellets were placed on Scotch tape and attached to an aluminum frame.

Proton-induced X-ray Emission Analysis {#Sec5}
--------------------------------------

A 2 MeV proton beam from the Van de Graaff accelerator was directed at the sample for a multitrace (K, Ca, Mn, Fe, Cu, Zn, and V) element analysis. Each sample was measured twice. Standard Reference Material 1577b Bovine Liver was also used. All the collected spectra were analyzed using GupixWin ver. 2.0 software. The statistical calculations were performed using Statistica 7.1 program. Differences between the studied rat groups were estimated using a nonparametric Kruskal--Wallis test. Full methodology was described in Acta Pol Pharm (2013) 70: 71--77.

Results {#Sec6}
=======

Vanadium {#d30e442}
--------

In all vanadium-treated animal groups, the level of this element was significantly (*p* \< 0.001) higher in comparison to not treated groups (Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}). No differences were observed between the vanadium organoligands used. Similar absence of differences was observed in animal groups not treated with vanadium.Fig. 1Vanadium level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 1Differences statistically significant for vanadium level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\*\*\**p* \< 0.001)DDiDi1Di2Di3Di4Di5CD--Di--Di1\*\*\*\*\*\*--Di2\*\*\*\*\*\*--Di3\*\*\*\*\*\*--Di4\*\*\*\*\*\*--Di5\*\*\*\*\*\*--C\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*--

Iron {#d30e705}
----

Iron level in the kidney presented only one significant difference between the two tested vanadium organoligands---Di1 vs. Di5 (Fig. [2](#Fig2){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). The obtained results indicate higher level of this metal in diabetic animals as compared to the control group. Presumably, more numerous groups would have shown significant differences.Fig. 2Iron level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 2Differences statistically significant for iron level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05)DDiDi1Di2Di3Di4Di5CD--Di--Di1--Di2--Di3--Di4--Di5\*--C--

Copper {#d30e937}
------

The copper level in the kidney is evidently associated with diabetes. In diabetic animals not treated with vanadium, the copper level was significantly higher in comparison to vanadium-treated rats and control groups. Vanadium treatment has reduced the level of this metal to a value close to the control group (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Vanadium compound used in the Di1 group had a lesser influence on copper decrease in diabetic animals.Fig. 3Copper level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 3Differences statistically significant for copper level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001)DDiDi1Di2Di3Di4Di5CD--Di--Di1\*\*--Di2\*\*\*\*--Di3\*\*\*\*--Di4\*\*\*\*--Di5\*\*\*\*--C\*\*\*\*\*\*\*--

Zinc {#d30e1199}
----

Vanadium treatment had very high influence on zinc level in the kidney (Fig. [4](#Fig4){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}). The obtained results have shown the decrease of zinc level in all vanadium-treated groups (*p* \< 0.01). On the other hand, diabetes increases the level of zinc in the kidney in comparison to the control group.Fig. 4Zinc level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 4Differences statistically significant for zinc level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001)DDiDi1Di2Di3Di4Di5CD--Di--Di1\*\*\*--Di2\*\*\*--Di3\*\*\*--Di4\*\*\*\*\*--Di5\*\*\*\*\*--C\*\*\*\*\*\*--

Manganese {#d30e1470}
---------

The manganese level in the kidney is associated with vanadium treatment. In all groups with vanadium administration, the level of manganese was higher in comparison to diabetic one and to control group (Fig. [5](#Fig5){ref-type="fig"} and Table [5](#Tab5){ref-type="table"}). No differences were observed between the vanadium organoligands used.Fig. 5Manganese level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 5Differences statistically significant for manganese level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05, \*\**p* \< 0.01)DDiDi1Di2Di3Di4Di5CD--Di--Di1\*\*--Di2\*\*--Di3\*\*--Di4\*\*\*\*--Di5\*\*\*\*--C\*\*\*\*--

Calcium {#d30e1731}
-------

The calcium level in the kidney seems to be not associated with vanadium treatment. The increase of the calcium level in the kidney in the diabetic animals was statistically significant in comparison to the control group (Fig. [6](#Fig6){ref-type="fig"} and Table [6](#Tab6){ref-type="table"}). However, in all diabetic groups, both with and without vanadium treatment, the calcium level was similar and higher than in case of the control group.Fig. 6Calcium level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 6Differences statistically significant for calcium level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05)DDiDi1Di2Di3Di4Di5CD--Di--Di1--Di2--Di3--Di4--Di5--C\*\*\*\*\*\*--

Potassium {#d30e1973}
---------

The potassium level was highest in diabetic and diabetic with insulin groups. Lowest level of potassium was observed in group treated with complex 4 (Fig. [7](#Fig7){ref-type="fig"} and Table [7](#Tab7){ref-type="table"}). The differences were statistically significant. Also, significant differences associated with type of vanadium compound were observed between groups Di1 and Di4.Fig. 7Potassium level in rat's kidney in different groups of animals (*D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control)Table 7Differences statistically significant for potassium level between animal groups: *D* diabetic, *Di* diabetic with insulin, *Di1* diabetic with insulin and vanadium complex 1, *Di2* diabetic with insulin and vanadium complex 2, *Di3* diabetic with insulin and vanadium complex 3, *Di4* diabetic with insulin and vanadium complex 4, *Di5* diabetic with insulin and vanadium complex 5, *C* control (\**p* \< 0.05)DDiDi1Di2Di3Di4Di5CD--DiDi1Di2Di3Di4\*\*\*Di5C-

Discussion {#Sec7}
==========

Diabetes and especially not treated diabetes deteriorating kidney function \[[@CR34]--[@CR36]\]. An increased glucose level in the blood during diabetes negatively influences the efficiency of this organ. An increase of thirst and urine production \[[@CR37]\] in not treated diabetes is visible. A high glucose level and hypertension have principal role in diabetic nephropathy. The dysfunction of the kidney drastically changes the total organism homeostasis and can cause death from renal failure. The most important role of the kidney is water and mineral recovery and elimination of nitrogen metabolites. High urine production by diabetic rats can cause loss of vital elements, which can increase the organism dysfunction \[[@CR38]\]. Vanadium administration in rats evidently increases the level of this element in the kidney more than 10 times in comparison to animals not treated with vanadium. This observation is similar for other studies in which the accumulation of vanadium in organs was observed after the treatment with ions of this metal \[[@CR39]--[@CR41]\]. The vanadium absorption from the gastrointestinal tract is associated with chemical structure of used compound. In case of used complexes in the present experiment, only two complexes (1 and 5) had pharmacokinetic study \[[@CR28]\]. Bioavailability of these complexes was 27--30 % and was higher in comparison to vanadyl sulfate was −18 %. For other complexes, pharmacokinetics study was not made for this time. An interesting observation was noted for zinc and copper levels. STZ-induced diabetes statistically increases both elements levels. Similar effects were reported by Sivikaya et al. \[[@CR42]\] for not treated STZ diabetes in the kidney. The increase of both elements can give information about an important role of these metals in diabetes development. It is probably associated with an increased uptake of zinc and copper in the kidney from blood during urine production. Treatment with vanadium in our work and with zinc in Sivikaya et al. work decreased levels of both elements in the kidney tissue. Vanadium complexes administered in a dose of 20 mg/kg/day (about 5--6 mg of pure vanadium depending of compound per kilogram per day) had higher influence on the zinc and copper level in the kidney than zinc in Sivikaya et al. work. As for copper, the level in all vanadium-treated groups was similar to the control group. The diabetic groups which were not treated with vanadium sometimes showed higher levels of copper than the control group. In the work of Sivikaya et al., zinc level in the kidney in zinc-treated animals was higher but zinc treatment can influence the total zinc level in the kidney. The question is if this increase of zinc and copper in the kidney of diabetic, not treated animal is associated with higher diuresis and/or elimination of these elements from other tissues. The increase of zinc and copper in those cases could possibly be explained by the fact that the accumulation of these elements in the kidney occurs to protect the organism from an important element loss. Zinc has an especially important role in insulin production and in protecting the organism against free radicals. There may also be a different explanation of the zinc and copper increase in the vanadium-treated animals. Streptozotocin destroys pancreatic island cells and after STZ administration zinc is eliminated also from the pancreas.

As for the calcium level in the kidney, an increase of this element in all diabetic groups was observed. Adding vanadium compounds did not affect the level of calcium in the tested tissue in all groups of animals (both treated and not treated). It is, therefore, possible to form a hypothesis that the calcium level in the kidney is closely connected with diabetes, both treated and not treated with vanadium compounds. The observed results are similar to the ones in the work of Dogru Pekine et al. \[[@CR43]\]. A different effect was observed in Sivikaya et al. \[[@CR42]\] where zinc treatment in STZ diabetic rats caused a decrease of the calcium level in the kidney of the animals.

The manganese level was statistically higher in all the vanadium-treated groups in comparison to the control and diabetic vanadium not-treated groups. It is difficult to compare the obtained results with other works because so far the vanadium and manganese interaction was not tested in the STZ diabetic model in the kidney. In the work of Sakai et al. \[[@CR44]\], an interaction between zinc and manganese in diabetic animals showed a similar increase of manganese in the kidney in zinc-treated animals.

The iron level in the kidney was the most variable element. Diabetes presented a trend in its increase in comparison to the control group but it was not significant. Vanadium treatment, especially the type of used complex, resulted in differences between all the five tested vanadium organoligands. Three of the tested complexes---1, 2, and 3---statistically increase the iron level in the kidney in comparison to the control group. On the other hand, the complex of vanadium five (Di5) decreased the iron level in the kidney in diabetic vanadium-treated animals in comparison to the control group. Differences between vanadium compounds and their influence on the iron level in the kidney were observed by Thompson et al. \[[@CR45]\], but they preformed an experiment with healthy animals. These differences may be associated with an oxidation state or absorption from the intestinal system.

All vanadium complexes used in the experiment were with organoligands. The changes observed in the level of the other elements were similar for the tested complexes in all cases except for the iron level. It can suggest that the type of organic ligand used has minimal influence on the measured metal level and the observed results are associated only with the vanadium action and its oxidation state. Probably, bioavailabilities of all tested complexes are very similar and animals had the some vanadium intake by examined organ. In case of iron, the situation is more complicated. Evidently, influence of used organoligands can be observed. It is especially exposed for complexes 1, 2, and 3 versus complex 5. This can suggests that the iron level can be correlated with an oxidation state of vanadium. In complexes 1--3, it is the vanadium (IV) oxidation state and for 4 and 5, it is vanadium (V) oxidation state. Analyzed interaction between iron level in kidney and vanadium treatment are few and require further research to verify the presented hypothesis. The obtained results also suggest that there are changes in metal levels in the investigated organ (the kidney) associated with diabetes. Metal supplementation can probably be useful in the treatment of this disease but further studies are required to confirm these findings. Another problem is contamination of used stainless steel chirurgical scissors and tweezers for iron and manganese level in kidney. During organ collection, the same procedure was used. Probability of contamination of the samples of these metals is very similar. Large differences of metals level in the analyzed samples was not observed within the groups and this suggesting about of comparable cross-contamination within the treatment group.
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